January 6, 2021

American CryoStem Enters into a Cooperative Research and Development Agreement (CRADA) to Develop Standardized Treatment Protocols

American CryoStem Corporation (OTC: CRYO), a clinical stage biotechnology Company, global licensor and a pioneer in autologous cellular processing and therapies announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) authorized by published code 15 U.S.C. 3710a of US Title 15 Commerce and Trade. (https://www.disa.mil/about/cto/crada-process-overview) The Collaborative work will be conducted at the Biomedical Research Laboratory in Bethesda, Maryland.
December 1, 2020
American CryoStem starts Post-Concussion Syndrome clinical trials

American CryoStem Announces Patient Recruitment and Additional Sub-Investigator for its Post-Concussion Syndrome (PCS) Phase I Clinical Trial

American CryoStem Corporation Issues Shareholder LetterEATONTOWN, NJ / ACCESSWIRE / December 1, 2020 / American CryoStem Corporation (OTC PINK: CRYO) a clinical stage biotechnology company, global […]
September 23, 2020

American CryoStem Announces: FDA has cleared its Investigational New Drug (IND) for Post-Concussion Syndrome for Phase I Clinical Trial

American CryoStem Corporation Issues Shareholder LetterEATONTOWN, NJ / ACCESSWIRE / September 23, 2020 / American CryoStem Corporation (OTC PINK:CRYO) is a clinical stage biotechnology company, global licensor, […]
June 29, 2020

American CryoStem Announces the Conversion of Debenture into Equity and Sale into the Market

American CryoStem Corporation Issues Shareholder LetterThe debt issuance has been executed in accordance with the terms of the Debenture contained in the Company\’s 10-Q through the […]
April 2, 2020
American CryoStem starts Post-Concussion Syndrome clinical trials

American CryoStem to Develop ATCELL™ Clinical Study for Duchene Muscular Dystrophy with RACEMD

American CryoStem Corporation Issues Shareholder LetterAmerican CryoStem to Develop ATCELL™ Clinical Study for Duchene Muscular Dystrophy with RACEMD April 1, 2020 EATONTOWN, NJ / ACCESSWIRE / April […]
December 5, 2019

American CryoStem Corporation Issues Shareholder Letter

American CryoStem Corporation Issues Shareholder LetterEATONTOWN, NJ / ACCESSWIRE / December 5, 2019 / American CryoStem Corporation (OTC PINK: CRYO) a leading strategic developer, marketer, and global […]
October 3, 2019

American CryoStem Announces:  American CryoStem Expands Investigator Team with Sub-Investigators for Post Concussive Syndrome IND

The Company and the Principal Investigator announce the addition of sub-investigators to the clinical trial team with extensive experience assessing and treating athletes and military personnel […]
September 18, 2019

American CryoStem Announces:  FDA Accepted its Investigational New Drug Application for Post Concussion Syndrome

ATCell™ Expanded Autologous, Adipose-Derived Mesenchymal Stem Cells Deployed via Intravenous Infusion for the Treatment of Post Concussion Syndrome (PCS) in Retired Military and Athletes EATONTOWN, NJ […]
September 12, 2019
American CryoStem starts Post-Concussion Syndrome clinical trials

American CryoStem Engages BioSolutions Clinical Research Center, LLC. and Principal Investigator for Chronic Concussive Syndrome IND

EATONTOWN, NJ / ACCESSWIRE / September 11, 2019 / American CryoStem Corporation (OTC PINK:CRYO) a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular […]